Update: Update in osteoporosis and metabolic bone disorders

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 3, 2007, Pages 747-753

  Shoback, Dolores ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b 111N Endocrine Research Unit   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CINACALCET; COLECALCIFEROL; DENOSUMAB; ETIDRONIC ACID; FIBROBLAST GROWTH FACTOR 23; FRIZZLED PROTEIN; IBANDRONIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; MATRIX PROTEIN; MONOCLONAL ANTIBODY; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PHOSPHATE; PLACEBO; PROCOLLAGEN C PROTEINASE; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TAMOXIFEN; VITAMIN D; WNT PROTEIN; ZOLEDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

BONE DENSITY; BONE NECROSIS; BONE STRENGTH; BONE TURNOVER; BREAST CANCER; CALCINOSIS; CANCER PREVENTION; CANCER RISK; CATARACT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BINDING; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; FRACTURE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HIP FRACTURE; HUMAN; HYPERPARATHYROIDISM; IN VIVO STUDY; ISCHEMIC HEART DISEASE; JAW OSTEONECROSIS; KIDNEY DISEASE; META ANALYSIS; METABOLIC BONE DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; PARATHYROID CARCINOMA; PARATHYROID FUNCTION; PATHOPHYSIOLOGY; PHOSPHATE METABOLISM; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK REDUCTION; SECONDARY OSTEOPOROSIS; STROKE; SYSTEMATIC REVIEW; TABLET FORMULATION; THROMBOEMBOLISM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; ANIMAL; BIOLOGICAL MODEL; METABOLISM; PARATHYROID DISEASE; PHYSIOLOGY;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; CALCINOSIS; CALCIUM; HUMANS; MODELS, BIOLOGICAL; OSTEOMALACIA; PARATHYROID DISEASES; PHOSPHATES; VITAMIN D;

EID: 33947537963     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0042     Document Type: Article

References (45)

1. Raisz LG 2005 Pathogenesis of osteoporosis. Concepts, conflicts, and prospects. J Clin Invest 115:3318-3325
2. Sambrook P, Cooper C 2006 Osteoporosis. Lancet 367:2010-2018
3. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster J-Y, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C 2005 Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE Study. J Bone Miner Res 20:1315-1322
4. Reginster J-Y, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD 2006 Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis 65:654-661
5. Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster J-Y, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM 2006 Intravenous ibandronate injections in postmenopausal women with osteoporosis: one year results from the Dosing Intravenous Administration Study. Arthritis Rheum 54:1838-1846
6. Black DM, Boonen S, Cauley J, Delmas P, Eastell R, Reid I, Rosario-Jansen T, Caminis J, Zhang J, Hu H, Cummings S 2006 Effect of once-yearly infusion of zoledronic acid 5 mg on spine and hip fracture reduction in postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial. J Bone Min Res 21(Suppl 1):S16
7. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group 2006 Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831
8. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM 2005 Effects of the calcimimetic cinacalcet HCL on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 68:1793-1800
9. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drueke TB, Cunningham J, Sherrard DJ, McCary LC, Olson JA, Turner SA, Martin KJ 2005 Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCL. Kidney Int 67:760-771
10. Silverberg SJ, Faiman C, Bilezikian JP, Shoback DM, Rubin MR, Smallridge R, Schwanauer LE, Olson KA, Klassen PS, PeacockM2006 Cinacalcet reduces hypercalcemia in patients with parathyroid carcinoma. J Bone Miner Res 21(Suppl 1):S440
11. Peacock M, Bilezikian JP, Klassen PS, Guo MD, Turner SA, Shoback D 2005 Cinacalcet hydrochloride maintains long-term normocalcemia in patients with primary hyperparathyroidism. J Clin Endocrinol Metab 90:135-141
12. Peacock M, Scumpia S, Bolognese M, Borofsky MA, Olson KA, McCary LM, Schwsanauer LE, Shoback DM 2006 Long-term control of primary hyperparathyroidism with cinacalcet. J Bone Miner Res 21(Suppl 1):S38
13. Kurosu H, Ogawa Y, Miyoshi M, Yamamota M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu M-C, Moe OW, Kuro-o M 2006 Regulation of fibroblast growth factor-23 signaling by Klotho. J Biol Chem 281:6120-6123
14. Urakawa I, Yamazaki Y, Shimada R, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774
15. Topaz O, Shurman DL, Berman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Zelikovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis. Nat Genet 36:579-581
16. Larsson T, Yu X, Davis SI, Draman MS, Mooney SD, Cullen MJ, White KE 2005 A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab 90:2424-2427
17. Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE 2006 Loss of DMP-1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315
18. Lorenz-Depiereux, Bastepe M, Benet-Pages A, Amyere M, Wagenstaller J, Muller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Juppner H, Strom TM 2006 DMP-1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250
19. Krishnan V, Bryant HU, Macdougald OA 2006 Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202-1209
20. Poole KE, Van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Lowik CW, Reeve J 2005 Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 19:1842-1844
21. Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD for the Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) 2004 Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
22. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
23. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR; Fracture Intervention Trial 2000 Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85:4118-4124
24. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, Satterfield S, Wallace RB, Bauer DC, Palermo L, Wehren LE, Lobmbardi A, Santora AC, Cummings SR for the FLEX Research Group 2006 Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 296:2927-2938
25. Ringe JD, Faber H, Farahmand P, Dorst A 2006 Effect of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 26:427-431
26. Odvina CV, Zerwekh JE, Rao S, Maalouf N, Gottschalk FA, Pak CYC 2005 Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90:1294-1301
27. Woo SB, Hellstein JW, Kalmar JR 2006 Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761
28. Ruggiero SL, Fantasia J, Carlson E 2006 Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433-441
29. Ruggiero S, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V 2006 Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2:7-14
30. Bilezikian JP 2006 Osteonecrosis of the jaw-do bisphosphonates pose a risk? N Engl J Med 355:2278-2281
31. Martino S, Cauley JA, Barrett-Connor E, Powles TJ, Mershon J, Disch D, Secrest RJ, Cummings S for the CORE Investigators 2004 Invasive breast cancer risk reduction in postmenopausal women with osteoporosis treated with raloxifen for 8 years: results form the Continuing Outcomes Relevant to Evista Trial. J Natl Cancer Inst 96:1751-1761
32. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, Bevers TB, Fehrenbacher L, Pajon Jr ER, Wade JL, Robidoux A, Margolese RG, James J, Lippman SM, Runowicz CD, Ganz PA, Reis SE, McCaskill-Stevens W, Ford LG, Jordan VC, Wolmark N, for the National Surgical Adjuvant Breast and Bowel Project (NSABP) 2006 Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial. JAMA 295:2727-2741
33. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, WengerNKfor the Raloxifene Use for the Heart (RUTH) Trial Investigators 2006 Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137
34. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ for the PaTH Study Investigators 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215
35. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM 2003 The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med 349:1216-1226
36. Finkelstein JS, Leder BZ, Burnett S-A, Wyland JJ, Lee H, de la Paz V, Gibson K, Neer RM 2006 Effects of teriparatide, alendronate, or both on bone turnover osteoporotic men. J Clin Endocrinol Metab 91:2882-2887
37. Black DM, Bilezikian JP, Ensrud KE, Greenspan SL, Palermo L, Hue T, Lang TF, McGowan JA, Rosen CJ for the PaTH Study Investigators 2005 One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med 353:555-565
38. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459-468
39. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, Devogelaer JP, Curiel MD, Sawicki A, Goemaere S, Sorensen OH, Felsenberg D, Meunier PJ 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 90:2816-2822
40. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R 2005 Estimates of optimal vitamin D status. Osteo Int 16:713-716
41. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE 2005 Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215-3224
42. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B 2005 Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257-2264
43. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, Bassford T, Beresford SAA, Black HR, Blanchette P, Bonds E, Brunner RL, Brzyski RG, Caan B, Cauley JA, Chlebowski RT, Cummings SR, Granek I, Hays J, Heiss G, Hendrix SL, Howard BV, Hsia J, Hubbell FA, Johnson KC, Judd H, Kotchen JM, Kuller LH, Langer RD, Lasser NL, Limacher MC, Ludlam S, Manson JE, Margolis KL, McGowan J, Ockene JK, O'Sullivan MJ, Phillips L, Prentice RL, Sarto GE, Stefanick ML, Van Horn L, Wactawski-Wende J, Whitlock E, Anderson GL, Assaf AR, Barad D, for the Women' Health Initiative Investigators 2006 Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669-683
44. Jan de Beur SM 2005 Tumor-induced osteomalacia. JAMA 294:1260-1267
45. Schiavi S 2006 Bone talk. Nat Genet 38:1230-1231